Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): Systematic review

BJU International

Volumn 110, Issue 5, 2012, Pages 614-628

  Cutress, Mark L ^a   Stewart, Grant D ^b   Zakikhani, Paimaun ^a   Phipps, Simon ^a   Thomas, Ben G ^a   Tolley, David A ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

adjuvant treatment; biopsy; percutaneous resection; upper tract transitional cell carcinoma; upper tract urothelial carcinoma; ureteroscopy

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; MITOMYCIN C;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE STUDY; COMORBIDITY; CONSERVATIVE TREATMENT; DIATHERMY; DISEASE SPECIFIC SURVIVAL; ELECTIVE SURGERY; EMERGENCY SURGERY; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; LASER SURGERY; LIFE EXPECTANCY; MEDLINE; MORTALITY; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; PERCUTANEOUS NEPHROSCOPIC RESECTION OF TUMOR; PRIORITY JOURNAL; PUBLICATION; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION; TUMOR ABLATION; TUMOR BIOPSY; URETEROSCOPIC ABLATION; URETEROSCOPY;

ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; BIOPSY; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; HUMANS; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME; URETER; URETEROSCOPY; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84865335212     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11068.x     Document Type: Review

References (94)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011; 59: 584-94
3. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG,. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998; 52: 594-601 (Pubitemid 28440164)
4. Stewart GD, Bariol SV, Grigor KM, Tolley DA, McNeill SA,. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 2005; 95: 791-3 (Pubitemid 40547208)
5. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
6. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224-33
7. Engelmyer EI, Belis JA,. Long-term ureteroscopic management of low-grade transitional cell carcinoma of the upper urinary tract. Tech Urol 1996; 2: 113-6
8. Jarrett TW, Sweetser PM, Weiss GH, Smith AD,. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol 1995; 154: 1629-35
9. Clark PE, Streem SB, Geisinger MA,. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol 1999; 161: 772-6 (Pubitemid 29422364)
10. Schmeller NT, Hofstetter AG,. Laser treatment of ureteral tumors. J Urol 1989; 141: 840-3 (Pubitemid 19108653)
11. Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML,. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology 2008; 71: 713-7
12. Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guerin therapy? Urology 2009; 73: 27-31
13. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735-40 (Pubitemid 44283660)
14. Weight CJ, Larson BT, Fergany AF, et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol 2010; 183: 1317-23
15. Weight CJ, Larson BT, Gao T, et al. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 2010; 76: 631-7
16. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008; 179: 468-73
17. Kaag MG, O'Malley RL, O'Malley P, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 2010; 58: 581-7
18. Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010; 116: 2967-73
19. Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L,. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol 1996; 156: 377-85 (Pubitemid 126445346)
20. Deligne E, Colombel M, Badet L, et al. Conservative management of upper urinary tract tumors. Eur Urol 2002; 42: 43-8 (Pubitemid 35339644)
21. Painter DJ, Denton K, Timoney AG, Keeley FX,. Ureteroscopic management of upper-tract urothelial cancer: an exciting nephron-sparing option or an unacceptable risk? J Endourol 2008; 22: 1237-9 (Pubitemid 351913518)
22. Pak RW, Moskowitz EJ, Bagley DH,. What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol 2009; 23: 341-6
23. Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA,. Long-term endoscopic management of upper tract urothelial carcinoma (UTUC): 20-year single centre experience. BJU Int 2012; doi:10.1111/j.1464-410X.2012. 11169.x
24. Andersen JR, Kristensen JK,. Ureteroscopic management of transitional cell tumors. Scand J Urol Nephrol 1994; 28: 153-7 (Pubitemid 24205373)
25. Gaboardi F, Bozzola A, Dotti E, Galli L,. Conservative treatment of upper urinary tract tumors with Nd:YAG laser. J Endourol 1994; 8: 37-41 (Pubitemid 24303446)
26. Grasso M, Fraiman M, Levine M,. Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies. Urology 1999; 54: 240-6 (Pubitemid 29367245)
27. Daneshmand S, Quek ML, Huffman JL,. Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer 2003; 98: 55-60 (Pubitemid 36741125)
28. Matsuoka K, Lida S, Tomiyasu K, Inoue M, Noda S,. Transurethral endoscopic treatment of upper urinary tract tumors using a holmium:YAG laser. Lasers Surg Med 2003; 32: 336-40 (Pubitemid 36760222)
29. Iborra I, Solsona E, Casanova J, Ricos JV, Rubio J, Climent MA,. Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol 2003; 169: 82-5 (Pubitemid 35461557)
30. Johnson GB, Fraiman M, Grasso M,. Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int 2005; 95 (Suppl. 2): 110-3 (Pubitemid 40314844)
31. Roupret M, Hupertan V, Traxer O, et al. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 2006; 67: 1181-7 (Pubitemid 43833463)
32. Reisiger K, Hruby G, Clayman RV, Landman J,. Office-based surveillance ureteroscopy after endoscopic treatment of transitional cell carcinoma: technique and clinical outcome. Urology 2007; 70: 263-6 (Pubitemid 47362249)
33. Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Elliott DS, Blute ML,. Imperative indications for conservative management of upper tract transitional cell carcinoma. J Urol 2007; 178: 792-7 (Pubitemid 47211089)
34. Lucas SM, Svatek RS, Olgin G, et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int 2008; 102: 172-6 (Pubitemid 351852585)
35. Cornu JN, Roupret M, Carpentier X, et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010; 28: 151-6
36. Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS Jr,. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 2010; 183: 2148-53
37. Raymundo EM, Lipkin ME, Banez LB, et al. Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol 2011; 25: 377-84
38. Tasca A, Zattoni F, Garbeglio A, Villi G, Bassi P, Meneghini A,. Endourologic treatment of transitional cell carcinoma of the upper urinary tract. J Endourol 1992; 6: 253-6
39. Fuglsig S, Krarup T,. Percutaneous nephroscopic resection of renal pelvic tumors. Scand J Urol Nephrol 1995; 172: 15-7
40. Plancke HR, Strijbos WE, Delaere KP,. Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br J Urol 1995; 75: 736-9
41. Patel A, Soonawalla P, Shepherd SF, Dearnaley DP, Kellett MJ, Woodhouse CR,. Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis. J Urol 1996; 155: 868-74 (Pubitemid 26052667)
42. Goel MC, Mahendra V, Roberts JG,. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol 2003; 169: 925-30
43. Suh RS, Faerber GJ, Wolf JS Jr,. Predictive factors for applicability and success with endoscopic treatment of upper tract urothelial carcinoma. J Urol 2003; 170: 2209-16 (Pubitemid 37413959)
44. Palou J, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H,. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol 2004; 172: 66-9 (Pubitemid 41615040)
45. Roupret M, Traxer O, Tligui M, et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol 2007; 51: 709-14 (Pubitemid 46110934)
46. Elliott DS, Segura JW, Lightner D, Patterson DE, Blute ML,. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology 2001; 58: 174-8 (Pubitemid 32728049)
47. Krambeck AE, Thompson RH, Lohse CM, et al. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol 2007; 177: 1721-6 (Pubitemid 46560644)
48. Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML,. Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. BJU Int 2008; 102: 1107-10
49. Keeley FX Jr, Bibbo M, Bagley DH,. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol 1997; 157: 1560-5 (Pubitemid 27171724)
50. Chromecki TF, Bensalah K, Remzi M, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol 2011; 8: 440-7
51. Elliott DS, Blute ML, Patterson DE, Bergstralh EJ, Segura JW,. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology 1996; 47: 819-25 (Pubitemid 26198905)
52. Liatsikos EN, Dinlenc CZ, Kapoor R, Smith AD,. Transitional-cell carcinoma of the renal pelvis: ureteroscopic and percutaneous approach. J Endourol 2001; 15: 377-83 (Pubitemid 32467080)
53. Rastinehad AR, Ost MC, Greenberg KL, et al. Does adjuvant BCG therapy reduce the incidence or time to recurrence in upper tract transitional cell carcinoma? A 20 years experience. J Urol 2007; 177 (Suppl.): 138
54. Lee BR, Jabbour ME, Marshall FF, Smith AD, Jarrett TW,. 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes. J Endourol 1999; 13: 289-94 (Pubitemid 29325596)
55. Waldert M, Karakiewicz PI, Raman JD, et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010; 105: 812-7
56. Hendin BN, Streem SB, Levin HS, Klein EA, Novick AC,. Impact of diagnostic ureteroscopy on long-term survival in patients with upper tract transitional cell carcinoma. J Urol 1999; 161: 783-5 (Pubitemid 29422366)
57. Boorjian S, Ng C, Munver R, et al. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology 2005; 66: 283-7 (Pubitemid 41138083)
58. El-Hakim A, Weiss GH, Lee BR, Smith AD,. Correlation of ureteroscopic appearance with histologic grade of upper tract transitional cell carcinoma. Urology 2004; 63: 647-50 (Pubitemid 38479400)
59. Tawfiek E, Bibbo M, Bagley DH,. Ureteroscopic biopsy: technique and specimen preparation. Urology 1997; 50: 117-9 (Pubitemid 27300375)
60. Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH,. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol 1997; 157: 33-7 (Pubitemid 26414922)
61. Williams SK, Denton KJ, Minervini A, et al. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J Endourol 2008; 22: 71-6
62. Painter DJ, Timoney AG, Denton K, Alken P, Keeley FX Jr,. The modern management of upper urinary tract urothelial cancer: tumour diagnosis, grading and staging. BJU Int 2007; 99: 973-7 (Pubitemid 46587922)
63. Tavora F, Fajardo DA, Lee TK, et al. Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol 2009; 33: 1540-6
64. Smith AK, Stephenson AJ, Lane BR, et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 2011; 78: 82-6
65. Chen GL, El-Gabry EA, Bagley DH,. Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis. J Urol 2000; 164: 1901-4
66. Guarnizo E, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED Jr, Sosa RE,. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol 2000; 163: 52-5
67. Shiraishi K, Eguchi S, Mohri J, Kamiryo Y,. Role of ureteroscopic biopsy in the management of upper urinary tract malignancy. Int J Urol 2003; 10: 627-30 (Pubitemid 38030610)
68. Brown GA, Matin SF, Busby JE, et al. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 2007; 70: 252-6 (Pubitemid 47362246)
69. Brien JC, Shariat SF, Herman MP, et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010; 184: 69-73
70. Skolarikos A, Griffiths TR, Powell PH, Thomas DJ, Neal DE, Kelly JD,. Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. Urology 2003; 61: 1146-50 (Pubitemid 36693990)
71. Somani BK, Moseley H, Eljamel MS, Nabi G, Kata SG,. Photodynamic diagnosis (PDD) for upper urinary tract transitional cell carcinoma (UT-TCC): evolution of a new technique. Photodiagnosis Photodyn Ther 2010; 7: 39-43
72. Somani B, Ahmed S, Nabi G, Kata SG,. Diagnosis of upper and lower urinary tract transitional cell carcinoma (TCC) using oral 5-Aminolevulanic acid (5-ALA) and phtodynamic diagnosis (PDD): prospective cohort study. BJU Int 2011; 108 (Suppl. 1): (P74) 47
73. Traxer O, Geavlete B, de Medina SG, Sibony M, Al-Qahtani SM,. Narrow-band imaging digital flexible ureteroscopy in detection of upper urinary tract transitional-cell carcinoma: initial experience. J Endourol 2011; 25: 19-23
74. Mian C, Mazzoleni G, Vikoler S, et al. Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur Urol 2010; 58: 288-92
75. Keeley FX Jr, Bagley DH,. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol 1997; 158: 2074-7 (Pubitemid 27481330)
76. Patel A, Fuchs GJ,. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol 1998; 159: 71-5 (Pubitemid 27525574)
77. Katz MH, Lee MW, Gupta M,. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B. J Endourol 2007; 21: 374-7 (Pubitemid 46764201)
78. Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE,. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 2011; 60: 955-60
79. Vasavada SP, Streem SB, Novick AC,. Definitive tumor resection and percutaneous bacille Calmette-Guerin for management of renal pelvic transitional cell carcinoma in solitary kidneys. Urology 1995; 45: 381-6
80. Thalmann GN, Markwalder R, Walter B, Studer UE,. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 2002; 168: 1381-5 (Pubitemid 35034127)
81. Orihuela E, Smith AD,. Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1988; 15: 425-31
82. Jabbour ME, Smith AD,. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am 2000; 27: 739-50
83. Sharpe JR, Duffy G, Chin JL,. Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol 1993; 149: 457-60 (Pubitemid 23094029)
84. Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol 2000; 38: 701-5
85. Okubo K, Ichioka K, Terada N, Matsuta Y, Yoshimura K, Arai Y,. Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int 2001; 88: 343-7 (Pubitemid 34066069)
86. Irie A, Iwamura M, Kadowaki K, Ohkawa A, Uchida T, Baba S,. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology 2002; 59: 53-7 (Pubitemid 34059307)
87. Miyake H, Eto H, Hara S, Okada H, Kamidono S, Hara I,. Clinical outcome of bacillus Calmette-Guerin perfusion therapy for carcinoma in situ of the upper urinary tract. Int J Urol 2002; 9: 677-80
88. Hayashida Y, Nomata K, Noguchi M, et al. Long-term effects of bacille Calmette-Guerin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology 2004; 63: 1084-8 (Pubitemid 38746808)
89. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L,. 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. Eur Urol Suppl 2009; 8: 453-7
90. USRDS. United States Renal Data System 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
91. Blute ML, Segura JW, Patterson DE, Benson RC Jr, Zincke H,. Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. J Urol 1989; 141: 1298-301 (Pubitemid 19151781)
92. Lee D, Trabulsi E, McGinnis D, Strup S, Gomella LG, Bagley D,. Totally endoscopic management of upper tract transitional-cell carcinoma. J Endourol 2002; 16: 37-41 (Pubitemid 34215526)
93. Sowter SJ, Ilie CP, Efthimiou I, Tolley DA,. Endourologic management of patients with upper-tract transitional-cell carcinoma: long-term follow-up in a single center. J Endourol 2007; 21: 1005-9 (Pubitemid 47608942)
94. Jabbour ME, Desgrandchamps F, Cazin S, Teillac P, Le Duc A, Smith AD,. Percutaneous management of grade II upper urinary tract transitional cell carcinoma: the long-term outcome. J Urol 2000; 163: 1105-7 (Pubitemid 30169371)